InVivium Capital
Venture capitalChicago · Seed–Late Stage · 6 people tracked
Also known as INVIVIUM CAPITAL MANAGEMENT, LLC
Investment thesis
InVivium Capital invests in transformative life sciences and healthcare innovation. The firm believes the healthcare industry is undergoing dramatic change that creates significant opportunity for groundbreaking innovation to meaningfully improve lives, health, and the quality of care people receive. Its stated mission is to work closely alongside exceptional founders and teams to bring transformational technologies to life.
Source: firm website, verified Aug 25, 2026.
Team · 6 people
from the firm's website
What they invest in
from 6 of 9 portfolio companiesBiotech ×6Healthtech ×3Deep Tech ×1Digital Health ×1Medical Devices ×1Mental Health ×1Robotics ×1
HQs:United States×6
Investments · 9 tracked
founders shown can be your intro pathBy year:2024 · 12023 · 12021 · 12020 · 14 dated
Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates.
BiotechDigital HealthMental HealthMountain View, US
Amit Etkin(Founder)inAdam Savitz(Executive Officer)Nicholas C. Smith(Executive Officer)Michael Hanley(Executive Officer)Aaron Weaver(Director)Po Yu (Jeff) Chen(Director)
Board seatMichael Liang· per SEC Form D
Co-investorsAble PartnersAlpha Wave GlobalK2 HealthVenturesKorify CapitalVivo CapitalWhat If Ventures+2 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalNorwest Venture PartnersRiverVest Venture PartnersSR One Capital Management+7 more
San Mateo, US
Board seatAmy Len Kobe· per SEC Form D · $50M raise · filed Nov 2021
Co-investorsAction Potential Venture Capital Ltd.
Co-investorsAccess Venture PartnersAdit Ventures Management, LlcAgilitas Private EquityAlba Infra PartnersALIVE Israel HealthTech FundAlkemi Growth Capital+73 more
Grove Biopharma develops Bionic Biologics, a synthetic drug modality that combines biologic and synthetic design to create cell-permeable molecules targeting intracellular protein-protein interactions.
BiotechDeep TechChicago, US
Geoffrey Duyk(CEO)
Co-investorsDCVC (Data Collective)DCVC BioPortal Innovations
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin M. Rollins(Executive Officer, Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)Harold E. "Barry" Selick(Chief Executive Officer & Director)
Co-investorsPoint72Baruch Future VenturesAgent CapitalRidgeback Capital
Onchilles Pharma is a biopharmaceutical company developing novel therapeutics based on scientific research to address unmet medical needs.
BiotechSan Diego, US
Lev Becker, Ph.D.(Director)Marc Nasoff(Chief Development Officer)Court Turner(Executive Officer, Director)Kevin Li, Ph.D.(Director)
A biotechnology company developing a next generation, fully recombinant botulinum toxin.
Virtual Incision develops a miniaturized robotic-assisted surgery (miniRAS) system called MIRA, designed to fit within hospitals' existing infrastructure.
BiotechHealthtechMedical DevicesRoboticsLincoln, US
Dmitry Oleynikov(Director)Shane Farritor(Executive Officer, Director)John P. Murphy(Executive Officer, Director)Mukund Srinivasan(Executive Officer)
BoardTom Shehab(Director)Fred Robertson(Director)
Co-investorsArboretum VenturesInvest NebraskaBaird CapitalEndeavour VisionPrairieGold Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioAlto NeuroscienceNYSE: ANROAvalyn Pharma IncNASDAQ: AVLN
Portfolio news
latest coverage across their companies
Alto Neuroscience · finance.yahoo.com · Aug 16, 2026
Virtual Incision · beatricedailysun.com · May 18, 2026
Avalyn Pharma Inc · investing.com · May 1, 2026
Grove Biopharma · xtalks.com · Jan 8, 2026
Onchilles Pharma · hitconsultant.net · Nov 7, 2025
Frequently asked questions
- How many investments has InVivium Capital made?
- InVivium Capital has 8 tracked investments, including 1 dated in the last 24 months.
- What stage does InVivium Capital invest at?
- InVivium Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does InVivium Capital focus on?
- InVivium Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is InVivium Capital located?
- InVivium Capital is headquartered in Chicago, US.
- Who does InVivium Capital co-invest with?
- InVivium Capital most often shares deals with Arboretum Ventures, DCVC (Data Collective), F-Prime Capital, among 20 tracked co-investors.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Ally Bridge Group is a global healthcare investment manager focused on high-impact life sciences innovation across private and public markets.